



SITE HEAD

Sofie Pattijn

Founder and Chief Technology Officer of
ImmunXperts, a Q² Solutions Company



GOSSELIES, BELGIUM

Key Features

The Gosselies laboratory supports research and development from discovery to exploratory clinical stages for our clients. We understand our diverse customers' needs and programs.

- Experience in all molecule types and with current modalities including oncolytic molecules, cells, gene therapy, monoclonal antibodies, and broad reagent materials
- We maintain a specialized and dedicated biostatistician on-site and approximately a third of our staff holds a Ph.D. or post-doctoral degree


Key Abilities

- Specialty CRO developing bioassays involving the human immune system for research & development in the fields of immunogenicity, immuno-oncology, and cell therapy
- Expertise in PD-1/PDL-1 blockers and wide range of first- and second-generation checkpoint inhibitors
- We manage functional testing and low immunogenicity with risk assessment and lead selection to reduce risk prior to in vivo or factor increasing monocytopoiesis (FIM) processes

Laboratory

- 4,300 square foot BSL-2/2+ laboratory
- 14,000 square feet of new labs under construction; completion date 2022
- Sample testing capacity (small batches R&D): 10,000
- Sample storage capacity: 100,000

Notable Certifications: Belgian Biobank License





OUR STORY

2014-2015

ImmunXperts is founded with a specific focus on developing high quality in vitro immunogenicity assays. The company partners with multidisciplinary experts and makes substantial investments in progressive technologies to advance their expertise in the field.

2016

In response to success in cancer treatments, ImmunXperts expands into immuno-oncology, developing new in vitro functional and potency assays, expanding to meet industry demand and trends.

2017

Growth dictates a move to new, dedicated facilities, providing 400 square meters (4,300 square feet) of space for expansion and development.

2019

Gosselies surpasses the 200 project and 70 client (across 18 countries) milestones.

2020

ImmunXperts is acquired by Nexelis, adding new services to Nexelis' portfolio and expanding its global footprint.

LAB EQUIPMENT AND TECHNIQUES

- BD Fortessa with 5 lasers – up to 20 parameters
- IncuCyte SX
- Macs Quant®10 3 lasers – up to 10 parameters
- Luminex
- HTRF
- Glomax Explorer
- Spectramax
- ELISpot / Fluorospot



We maintain a specialized and dedicated biostatistician on-site and approximately a third of our staff holds a Ph.D. or post-doctoral degree.

ABOUT NEXELIS, a Q² Solutions Company

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

GOSSELIES, BELGIUM

Street Clement Ader 16, 6041
Charleroi, Belgium
+32 71 96 01 33

SEATTLE, WA, USA
LAVAL, CANADA, QC
INDIANAPOLIS, IN, USA
MARBURG, GERMANY
PORTON DOWN, UK
BEIJING, CHINA